Japfa’s revenue for its Indonesia subsidiary grew 7% y-o-y, while also registering 3% growth in its animal protein - others (APO) business, largely from Vietnam.
DBS Group Research and CGS International (CGSI) analysts are keeping their "buy" and "add" calls on Japfa (SGX:UD2
) following the company’s 1HFY2024 ended June results release.
For its 1HFY2024, Japfa’s revenue came in at US$2.3 billion ($3.08 billion), up 6% y-o-y. Earnings were US$52 million, reversing from the US$54 million loss last year — this equates to about 80% of DBS’s FY2024 projections.
